VIVALIS ANNOUNCES A NEW EB66® CELL LINE RESEARCH LICENSE WITH THE ITALIAN ANIMAL HEALTH VACCINE COMPANY FATRO

VIVALIS ANNOUNCES A NEW EB66^® CELL LINE RESEARCH LICENSE WITH THE ITALIAN ANIMAL HEALTH VACCINE COMPANY FATRO

Nantes & Lyon (France) - February 05^th, 2012 - VIVALIS (NYSE Euronext: VLS) announced today that it
has signed a research license agreement with the Italian animal health vaccine company FATRO. This license allows for the assessment of several viruses in EB66^® cells.

Franck Grimaud, CEO, and Majid Mehtali, CSO, co-managers of VIVALIS jointly stated, "Our development into the animal vaccines market with our EB66^® cell line is continuing and intensifying. We have announced the signing of a new research license agreement with FATRO, an Italian laboratory well known throughout the animal health world. The EB66^® cell line continues to stand and as the cell line of choice for the vaccine manufacturing over traditional manufacturing systems, for both human and animal health vaccines."

Terms of the agreement were not disclosed.

**********************

Next Financial Press Release

February 14^th, 2013, after NYSE Euronext market closing:
2012 fourth-quarter and annual revenues

About VIVALIS (www.vivalis.com)
Vivalis (NYSE-Euronext: VLS) is a biopharmaceutical company that provides innovative cell-based solutions to the biotechnology and pharmaceutical industry for the manufacture of vaccines and recombinant proteins, and develops monoclonal antibodies for the prevention and treatment of diseases with unmet medical needs. Vivalis' expertise and intellectual property are leveraged in two main areas:

1. EB66^® Cell Line

Vivalis offers research and commercial licenses for its EB66^® cell line, derived from duck embryonic stem cells, to pharmaceutical and biotechnology companies for the production of therapeutic and prophylactic viral vaccines, virosomes, VLPs and recombinant proteins, including monoclonal antibodies. Clinical trials of EB66^® produced vaccines are currently on-going in the USA and Japan and in 2012 a vaccine produced in EB66^® cells received market approval in Japan for use in animal health. Through these programs, Vivalis receives an upfront payment, clinical stage milestone payments along with royalties on licensees' net sales.

1. VIVA|Screen(TM) Human Antibody Discovery Platform

Customized solutions for the discovery, development and production of rare, fully human monoclonal antibodies are offered by Vivalis. Through these programs, Vivalis receives payments associated with the funding of discovery research, an upfront payment, clinical stage milestone payments along with royalties on net sales of licensed antibodies that are commercially developed from the use of the platform.

Based in Nantes and Lyon (France) and in Toyama (Japan), Vivalis was founded in 1999 by the Group Grimaud (approx. 1,700 employees), one of the worldwide leaders in animal genetic selection. Vivalis has established more than 30 partnerships and licenses with world leaders in biopharmaceutical industry, including Sanofi Pasteur, GlaxoSmithKline Biologicals, Transgene, Pfizer Animal Health, Kaketsuken, Kitasato Daiichi Sankyo Vaccine, Merial, Merck Animal Health and SAFC Biosciences. Vivalis is a member of the French ATLANTIC BIOTHERAPIES and LYON BIOPOLE bio-clusters and a member of the Japanese HOKURIKU INNOVATION CLUSTER FOR HEALTH SCIENCE based in Toyama.

This document contains forward-looking statements and comments on the company's objectives and strategies. No guarantee can be given to any of the events anticipated by the forward-looking statements contained in this document, which are subject to inherent risks, including risk factors described in the company's Document de Référence, changes in economic conditions, the financial markets or the markets in which the company operates.

Contacts